Received for publication May 24, 2006.
Revised July 11, 2006.
Accepted for publication July 31, 2006.

A 3D-QSAR study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase II by substituted purine analogs

Abstract

Based on the topoisomerase II catalytic inhibitory activity of a previous hit compound, NSC35866, we screened 40 substituted purines or purine-like compounds from the National Cancer Institute repository for their ability to inhibit the ATPase activity of human topoisomerase II. Several compounds including NSC348400, NSC348401 and NSC348402 were inhibitory at sub-micro molar concentrations. 3D-QSAR models using CoMFA and CoMSIA analyses were constructed using 24 of these compounds. The ability of 10 selected compounds to inhibit the complete DNA strand passage reaction of topoisomerase II correlated well with their potency as ATPase inhibitors. None of the 40 compounds significantly increased levels of the topoisomerase II - DNA covalent complex, suggesting that they functioned as catalytic topoisomerase II inhibitors and not as topoisomerase II poisons. Although some of these compounds could antagonize the effect of etoposide on the level of topoisomerase II - DNA covalent complex formation in vitro, in contrast to NSC35866, they were not capable of antagonizing etoposide-induced cytotoxicity and DNA strand breaks in cells. Two independently selected human SCLC cell lines with reduced topoisomerase II expression displayed cross-resistance to NSC348400, NBSC348401 and NSC348402, while an MDR1 line was fully sensitive. These results suggest that topoisomerase II is a functional cellular target for most of these substituted purine compounds and that these compounds do not display MDR1 liability.

Key words: Structure-activity relationships and modeling, Topoisomerases

This article has been cited by other articles:

				H. Liang, X. Wu, J. C. Yalowich, and B. B. Hasinoff A Three-Dimensional Quantitative Structure-Activity Analysis of a New Class of Bisphenol Topoisomerase II{alpha} Inhibitors Mol. Pharmacol., March 1, 2008; 73(3): 686 - 696. [Abstract] [Full Text] [PDF]